Europe EV Demand Surges as Fuel Prices Rise Amid Iran Conflict 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Elon Musk Becomes World's First Trillionaire After SpaceX IPO Surge 
Japan Signals Readiness to Intervene as USD/JPY Nears 161 Amid Yen Weakness 
SoftBank Vision Fund CFO Navneet Govil to Exit After Decade-Long Tenure 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Oil Prices Recover Slightly as U.S. Crude Inventories Fall, But Iran Deal Caps Gains 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Asian Currencies Stabilize as Dollar Holds Near Two-Month High After Fed Hawkish Signal 
German Industry Employment Falls to Lowest Level in a Decade 
Trump Administration Closes Delta Air Lines Investigation Over 2024 CrowdStrike Outage 
Trump Questions USMCA Renewal as Trade Talks Continue 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
SpaceX Stock Soars After Historic IPO, Reaches $2.5 Trillion Market Value 
U.S.-Iran Peace Deal Extends Gulf Ceasefire, Reopens Strait of Hormuz 
Lotte Biologics has inked a memorandum of understanding (MOU) with Roche Diagnostics to bolster its Contract Development and Manufacturing Organization (CDMO) capabilities. This collaboration signifies major diagnostics, hardware, and automation advancements for Lotte's upcoming Korean production plants.
On Wednesday, Aug. 9, Lotte Biologics said it will work with Roche Diagnostics to improve the productivity and quality of its productions. The company said they would also team up to establish hardware and automation systems for Lotte's upcoming production plants in Korea, as per Korea Joongang Daily.
The MOU was signed at Roche Diagnostics CustomBiotech Center in Penzberg, Germany. Lotte Biologics' chief executive officer, Richard Lee; Roche Diagnostics CustomBiotech's vice president, Rainer Mueller; and Roche Diagnostics Korea's general manager, Kit Tang, were all present at the signing ceremony.
With the deal in place, Lotte Biologics aims to amplify its credibility with future global clients. The agreement will also serve as the forefront to underpin and shore up Roche Diagnostics' supply network in the Asian market. This will also give better treatment access to patients around the world.
"Through this MOU, we plan to enhance the production process capabilities of our Korean Mega Plant in collaboration with Roche Diagnostics," Lotte Biologics chief Richard Lee said in a press release. "Through synergy with Roche Diagnostics, an industry leader in the in vitro diagnostic field, LOTTE hopes to improve the efficiency of its operations at the forthcoming Korean Mega Plant, simultaneously augmenting the quality of our manufacturing and fulfilling customer needs."
Finally, Business Korea reported that Lotte Biologics and Roche Diagnostics will cooperate on various business fronts, including installing automation systems at the former's Mega Plants that will be built in Korea. The latter will also provide technical consulting and equipment support for the facilities.
Photo by: Lotte Biologics Newsroom
